Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

245
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
245
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerated diabetic wound healing using a chitosan-based nanomembrane incorporating nanovesicles from Aloe barbadensis, Azadirachta indica, and Zingiber officinale.

International journal of biological macromolecules·2025
Same author

Therapeutic effects of OXY- Exo<sup>Aloe</sup> in diabetic wound injury.

Biochemical and biophysical research communications·2024
Same author

Left Ventricular Septal Avulsion in the Setting of Blunt Cardiac Injury.

The Annals of thoracic surgery·2022
Same author

Reducing Time to Discharge after Chemotherapy by Standardizing Workflow and Providing Outpatient Intravenous Hydration.

Pediatric quality & safety·2021
Same author

A comparative evaluation of fracture load of monolithic and bilayered zirconia crowns with and without a cervical collar: an in vitro study.

Medicine and pharmacy reports·2019
Same author

Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease-state-of-the-evidence and clinical recommendations.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2017

Related Experiment Video

Updated: Jan 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K

The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways.

Vandana Pathak1, Claudia Arredondo Pimentel2, Elli Cooney1

  • 1Global Regulatory Affairs (Oncology), Amgen Inc, Thousand Oaks, USA.

Therapeutic Innovation & Regulatory Science
|May 26, 2025
PubMed
Summary

Tarlatamab-dlle (IMDELLTRA) is now approved as a novel bispecific T-cell engager therapy for extensive-stage small cell lung cancer. This marks a significant advancement in treating patients with relapsed disease after chemotherapy.

Keywords:
Expedited regulatory pathwaysMarketing authorization applicationProject confirmProject optimusProject orbisRegulatory approvalTarlatamab

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Related Experiment Videos

Last Updated: Jan 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Extensive-stage small cell lung cancer (ES-SCLC) has limited treatment options after progression on platinum-based chemotherapy.
  • Targeting DLL3 presents a promising therapeutic strategy for SCLC.
  • Bispecific T-cell engager (BiTE) technology offers a novel approach to redirect T-cells for cancer cell killing.

Purpose of the Study:

  • To present the case study of tarlatamab-dlle (IMDELLTRA) approval.
  • To highlight the regulatory pathways facilitating expedited development and review.
  • To discuss the role of special designations and FDA initiatives in accelerating drug approval.

Main Methods:

  • Review of regulatory submissions and approval processes for tarlatamab-dlle.
  • Analysis of global expedited pathways and special designations utilized.
  • Examination of US FDA's Oncology Center of Excellence contributions.

Main Results:

  • Tarlatamab-dlle (IMDELLTRA) received FDA approval on May 16, 2024.
  • It is the first FDA-approved DLL3-targeting bispecific T-cell engager therapy.
  • The approval was expedited through various regulatory mechanisms.

Conclusions:

  • Tarlatamab-dlle represents a significant therapeutic advancement for adult patients with ES-SCLC.
  • The expedited development and approval process underscores the effectiveness of regulatory initiatives.
  • This case study offers insights into navigating global regulatory landscapes for novel cancer therapies.